<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318899</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1247/REK sør-øst</org_study_id>
    <nct_id>NCT04318899</nct_id>
  </id_info>
  <brief_title>Predictors of Clinical Course and Treatment Response in DBT Programmes</brief_title>
  <official_title>Predictors of Clinical Course and Treatment Response in Patients Having Received Dialectical Behaviour Therapy Delivered by Clinical Units in the Norwegian Network for Clinical Evaluation and Quality in DBT Programmes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Ostfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is a collaboration between The National Centre for Suicide Research and&#xD;
      Prevention (NSSF) and clinical units with Dialectical Behaviour Therapy (DBT) programmes. A&#xD;
      methodological and technological platform has been established that enables clinicians to&#xD;
      deliver high quality treatments over extended periods of time, to evaluate their own&#xD;
      performance and productivity and to report it in a uniform and systematic way that will&#xD;
      enable comparison across clinical settings and programmes. The collected data constitute the&#xD;
      basis for conducting the clinical study with the overall aim to study predictors of the&#xD;
      clinical course and treatment response in patients admitted to DBT programmes in Norway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the project is to collect data from systematic and uniform clinical assessments to&#xD;
      study predictors of the clinical course and treatment response in patients admitted to and&#xD;
      treated in clinical units delivering Dialectical Behaviour Therapy in Norway.&#xD;
&#xD;
      Aims and research questions:&#xD;
&#xD;
      The study will address the following main research questions:&#xD;
&#xD;
        1. Which patient characteristics (sociodemographic variables, psychiatric&#xD;
           diagnoses/comorbidities, previous suicidal and self-harming behaviour, previous&#xD;
           treatment history), predict a favourable clinical course and treatment response?&#xD;
&#xD;
        2. Which factors mediate the clinical change in key outcomes such as a) target symptom&#xD;
           levels (depression, hopelessness, suicidal ideation, borderline symptoms etc.), b)&#xD;
           function levels (emotion regulation capacity, use of coping skills, social functioning,&#xD;
           occupational / academic performance level etc.), c) problem behaviours (suicide&#xD;
           attempts, non-suicidal self-harm, substance abuse, eating disorder symptoms etc.), d)&#xD;
           global functioning and e) the use of emergency treatment services.&#xD;
&#xD;
        3. What are significant moderators of treatment response with respect to key clinical&#xD;
           outcomes (mentioned above)?&#xD;
&#xD;
        4. Which of the treatment modalities are evaluated as the most salient and helpful by&#xD;
           patients who receive the treatment according to their age, gender, psychiatric diagnoses&#xD;
           and previous treatment history?&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A uniform protocol for psychiatric diagnostics and clinical assessment of patients who&#xD;
      receive treatment at the participating clinical units will be used. Since some participating&#xD;
      clinical units will treat adult patients and some will treat children and adolescents, the&#xD;
      protocol will offer assessment instrument suitable for the specific age group whenever this&#xD;
      is relevant. The evaluation system includes assessments at baseline before treatment starts,&#xD;
      evaluation at several time points during the treatment period, at termination of treatment&#xD;
      and at follow-up. Assessments will be made both through interviews and ratings made by&#xD;
      therapists and through self-report from patients.&#xD;
&#xD;
      Self-reports will be filled out electronically by patients, on tablets stationed at each&#xD;
      participating clinical unit. At intervals patients will also provide self-rated information&#xD;
      on dimensions such as emotions, cognitions and impulsive behaviour several times per day&#xD;
      through a mobile app developed specifically for the purpose, so-called Ecological Momentary&#xD;
      Assessment (EMA). Interview data and ratings will be entered into the database by each&#xD;
      clinician to tablets in a similar fashion as self-report data from patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-harm behaviour</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of self-harm episodes (split on suicide attempts and non-suicidal self-harm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal Ideation (adolescents)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Suicidal Ideation Questionnaire (SIQ-Jr). Min=0, Max=90. Higher scores indicate worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>1 week</time_frame>
    <description>MADRS (Montgomery Asberg Depression Rating Scale).Min=0, Max=60. Higher scores indicate worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal Ideation (adults)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Beck Scale for Suicidal Ideation (BSS). MIn=0, Max=38. Higher scores indicate worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms (adolescents)</measure>
    <time_frame>1 week</time_frame>
    <description>Moods and Feelings Questionnaire (MFQ). Min=0, Max=26. Higher scores indicate worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive symptoms (adults)</measure>
    <time_frame>1 week</time_frame>
    <description>Beck Depression Inventory (BDI). Min=0, Max=63. Higher scores indicate worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Borderline Symptoms</measure>
    <time_frame>1 week</time_frame>
    <description>Borderline Symptom List (BSL-23). Min=0, Max=92. Higher scores indicate more symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopelessness</measure>
    <time_frame>1 week</time_frame>
    <description>Beck Hopelessness Scale (BHS). Min=0, Max=20. Higher scores indicate more hopelessness.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Self Harm</condition>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Dialectical Behaviour Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dialectical Behaviour Therapy adapted for adolescents (DBT-A)</intervention_name>
    <description>DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus &amp; Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.</description>
    <arm_group_label>Dialectical Behaviour Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dialectical Behaviour Therapy - Standard version (DBT)</intervention_name>
    <description>DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.</description>
    <arm_group_label>Dialectical Behaviour Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of repeated deliberate self harm&#xD;
&#xD;
          -  Satisfies criteria of Diagnostic and Statistical Manual (DSM-IV) Borderline&#xD;
             Personality Disorder as measured by Structured Clinical Interview for the DSM&#xD;
             (SCID-II) in addition to the self-destructive criterion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychotic disorders&#xD;
&#xD;
          -  Anorexia Nervosa&#xD;
&#xD;
          -  Substance dependence disorder&#xD;
&#xD;
          -  Mental retardation (IQ less than 70)&#xD;
&#xD;
          -  Asperger syndrome/autism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Mehlum, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Egil Haga, PhD</last_name>
    <phone>+4722923442</phone>
    <email>egil.haga@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Mehlum, MD PhD</last_name>
    <phone>+4722923442</phone>
    <email>lars.mehlum@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moss DPS/Østfold sykehus HF</name>
      <address>
        <city>Moss</city>
        <zip>1535</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Utne Haldorsen Kalla, MD</last_name>
      <email>eva.utne.haldorsen.kalla@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Søndre Oslo DPS/Oslo Universitetssykehus HF</name>
      <address>
        <city>Oslo</city>
        <zip>1281</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tone Enge Berthelsen, MA</last_name>
      <email>UXBETG@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk senter ytre Helgeland/Helgelandssykehuset HF</name>
      <address>
        <city>Sandnessjøen</city>
        <zip>8800</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gry E Konradsen, Psych Nurse</last_name>
      <email>Gry.Elin.Konradsen@Helgelandssykehuset.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bjerketun behandlingshjem/Vestreviken HF</name>
      <address>
        <city>Sandvika</city>
        <zip>1341</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristoffer Ødegård, MA</last_name>
      <email>oedkri@vestreviken.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BUP Lian/St Olavs Hospital HF</name>
      <address>
        <city>Trondheim</city>
        <zip>7024</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marthe Stornes, MA</last_name>
      <email>marthe.stornes@stolav.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Linehan, M.M. (1993a). Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press</citation>
  </reference>
  <reference>
    <citation>Linehan, M.M. (1993b). Skills training manual for treating borderline personality disorder. New York: Guilford Press</citation>
  </reference>
  <reference>
    <citation>Miller, A.L., Rathus J.H., Linehan, M.M. (2007). Dialectical behavioral therapy with suicidal adolescents. New York: Guilford Press</citation>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Mehlum</investigator_full_name>
    <investigator_title>Professor dr med</investigator_title>
  </responsible_party>
  <keyword>self harm</keyword>
  <keyword>dialectical behaviour therapy</keyword>
  <keyword>borderline personality disorder</keyword>
  <keyword>emotional dysregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
    <mesh_term>Self-Injurious Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

